Bristol Myers Squibb has joined Brandon Capital, a leading Australian life sciences private equity firm, in supporting Pathios Therapeutics' Series B financing.
-
Latest News BMS and Australian venture capital firm back immunotherapy company Pathios Therapeutics April 23, 2024
-
Latest News Mark Butler announces NHMRC funding for six telehealth research projects April 23, 2024The Albanese Government has announced that the National Health and Medical Research Council will invest $5 million in six research projects focused on telehealth.
-
Latest News MTPConnect says Australia poised to lead revolution in radiopharmaceuticals April 18, 2024MTPConnect says a new discussion paper reveals how Australia is ready to play a leading role in the rise of the global radiopharmaceutical industry.
-
Latest News Telix Pharmaceuticals records another quarter of strong revenue growth April 18, 2024Telix Pharmaceuticals (ASX:TLX) has reported an 18 per cent increase in revenue for the first three months of the calendar year 2024.
-
Latest News Immutep appoints research institute to conduct first-in-human study of IMP761 April 18, 2024Immutep Limited (ASX:IMM) has entered into an agreement with the Centre for Human Drug Research (CHDR) in the Netherlands to perform a first-in-human clinical study of IMP761.
-
Latest News Bioxyne receives commitments to raise funds to further product development April 18, 2024Australian life sciences, pharmaceutical and consumer health products company Bioxyne (ASX:BXN) has received firm commitments to raise $1.45 million.
-
Latest News Seaport Therapeutics receives $100 million in funding to maximise Monash invention April 16, 2024US clinical-stage biopharmaceutical company Seaport Therapeutics has closed a US$100 million oversubscribed Series A financing round to progress a pipeline using a platform developed at the Monash Institute of Pharmaceutical Sciences.
-
AusBiotech AusBiotech welcomes the Medical Science Co-Investment Plan April 16, 2024The Australian Government has launched its Medical Science Co-Investment Plan, identifying four key investment opportunity areas in the medical science priority area: medical devices, complex therapeutics, digital health, and sustainability.
-
Latest News Telix's TLX101-CDx granted fast track designation by US FDA April 16, 2024The US FDA has granted fast-track designation to Telix Pharmaceuticals (ASX:TLX) investigational glioma imaging product Pixclara (TLX101-CDx).
-
Latest News First Turkish patient treated with OncoSil cancer treatment device April 16, 2024Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) has announced the first treatment utilising the OncoSil device on a patient residing in Turkey.
-
Latest News dorsaVi enters aged care market with proprietary ‘natural movement’ AI algorithm April 16, 2024dorsaVi CEO Dr Andrew Ronchi said, “I am delighted to announce the release of our Natural Movement Algorithm which will drive new commercial applications within the aged care sector domestically and internationally."
-
Latest News Next Science says study shows efficacy in reducing infection when used in knee arthroplasty April 16, 2024Next Science (ASX:NXS) has announced the publication of a study it says demonstrates the efficacy of XPERIENCE in decreasing periprosthetic joint infection following a Total Knee Arthroplasty.
-
Latest News PYC Therapeutics secures investor commitments to support pipeline development April 11, 2024PYC Therapeutics has received binding commitments for the full $74.6 million contemplated under the Accelerated Non-Renounceable Entitlement Offer announced on 14 March 2024.
-
AusBiotech Join the Australian delegation to BIO 2024 April 11, 2024AusBiotech and MTPConnect partner to support this year’s BIO 2024 mission to showcase Australia’s outstanding life science innovations, innovators, and unique capabilities.
-
Latest News Atmo Biosciences reaches primary endpoints in pivotal clinical study for initial indication April 11, 2024Atmo Biosciences, a company commercialising the world’s first ingestible gas-sensing capsule that provides insights into gut health, has reached its primary endpoints in a pivotal clinical study to assess whole and regional gut transit time in subjects with suspected gastrointestinal motility disorders.
-
Latest News CLEO appoints organisation to manage US ovarian cancer clinical trials April 11, 2024CLEO (ASX:COV) has appointed Lindus Health, a US-based company, to manage US clinical trials for its ovarian cancer blood test.
New Stories
-
AusBiotech announces incoming CEO
April 23, 2024 - - AusBiotech -
Osteopore launches first first-in-human clinical trials begin in Singapore
April 23, 2024 - - Latest News -
Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate
April 23, 2024 - - Latest News -
Mark Butler announces NHMRC funding for six telehealth research projects
April 23, 2024 - - Latest News -
BMS and Australian venture capital firm back immunotherapy company Pathios Therapeutics
April 23, 2024 - - Latest News -
AusBiotech submits response on NSW Innovation Blueprint
April 18, 2024 - - AusBiotech -
Telix Pharmaceuticals records another quarter of strong revenue growth
April 18, 2024 - - Latest News